Health Professional Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Professional Times.

Press releases published on July 30, 2026

Jul. 30, 2026

Diakonos Oncology Announces First Patients Dosed in Phase 1/2 DOC-RM Study of DOC1021 in Refractory Melanoma

Indeterminate GlobeNewswire

Jul. 30, 2026

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

Indeterminate GlobeNewswire

Jul. 30, 2026

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour

Indeterminate GlobeNewswire

Jul. 30, 2026

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

Indeterminate GlobeNewswire

Jul. 30, 2026

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

Indeterminate GlobeNewswire

Jul. 30, 2026

Plymouth Rock Assurance is the First U.S. Carrier to Offer Home Insurance Quoting Through ChatGPT

Indeterminate GlobeNewswire

Jul. 30, 2026

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

Indeterminate GlobeNewswire

Jul. 30, 2026

Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share

Indeterminate GlobeNewswire

Jul. 30, 2026

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Indeterminate GlobeNewswire

Jul. 30, 2026

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

Indeterminate GlobeNewswire

Jul. 30, 2026

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Indeterminate GlobeNewswire

Jul. 30, 2026

NewGen Provides Update on K25.ai Investment and Strengthened Financial Position

Indeterminate GlobeNewswire

Jul. 30, 2026

Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial

Indeterminate GlobeNewswire

Jul. 30, 2026

NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness

Indeterminate GlobeNewswire

Jul. 30, 2026

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

Indeterminate GlobeNewswire

Jul. 30, 2026

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

Indeterminate GlobeNewswire

Jul. 30, 2026

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

Indeterminate GlobeNewswire

Jul. 30, 2026

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

Indeterminate GlobeNewswire

Jul. 30, 2026

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

Indeterminate GlobeNewswire

Jul. 30, 2026

Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

Indeterminate GlobeNewswire